Literature DB >> 35569056

The Liver X Receptor Is Selectively Modulated to Differentially Alter Female Mammary Metastasis-associated Myeloid Cells.

Liqian Ma1, Hashni Epa Vidana Gamage1, Srishti Tiwari1, Chaeyeon Han1, Madeline A Henn1, Natalia Krawczynska1, Payam Dibaeinia2, Graeme J Koelwyn3, Anasuya Das Gupta1, Rafael Ovidio Bautista Rivas1, Chris L Wright4, Fangxiu Xu4, Kathryn J Moore3,5, Saurabh Sinha2,6,7, Erik R Nelson1,6,7,8,9,10.   

Abstract

Dysregulation of cholesterol homeostasis is associated with many diseases such as cardiovascular disease and cancer. Liver X receptors (LXRs) are major upstream regulators of cholesterol homeostasis and are activated by endogenous cholesterol metabolites such as 27-hydroxycholesterol (27HC). LXRs and various LXR ligands such as 27HC have been described to influence several extra-hepatic biological systems. However, disparate reports of LXR function have emerged, especially with respect to immunology and cancer biology. This would suggest that, similar to steroid nuclear receptors, the LXRs can be selectively modulated by different ligands. Here, we use RNA-sequencing of macrophages and single-cell RNA-sequencing of immune cells from metastasis-bearing murine lungs to provide evidence that LXR satisfies the 2 principles of selective nuclear receptor modulation: (1) different LXR ligands result in overlapping but distinct gene expression profiles within the same cell type, and (2) the same LXR ligands differentially regulate gene expression in a highly context-specific manner, depending on the cell or tissue type. The concept that the LXRs can be selectively modulated provides the foundation for developing precision pharmacology LXR ligands that are tailored to promote those activities that are desirable (proimmune), but at the same time minimizing harmful side effects (such as elevated triglyceride levels).
© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  27-hydroxycholesterol; SLXRM; SLiMs; breast cancer; liver X receptor; myeloid cell; nuclear receptor; selective LXR modulator

Mesh:

Substances:

Year:  2022        PMID: 35569056      PMCID: PMC9188661          DOI: 10.1210/endocr/bqac072

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   5.051


  60 in total

Review 1.  Oxysterols: modulators of cholesterol metabolism and other processes.

Authors:  G J Schroepfer
Journal:  Physiol Rev       Date:  2000-01       Impact factor: 37.312

Review 2.  Development of selective androgen receptor modulators (SARMs).

Authors:  Ramesh Narayanan; Christopher C Coss; James T Dalton
Journal:  Mol Cell Endocrinol       Date:  2017-06-15       Impact factor: 4.102

Review 3.  Humanized hemato-lymphoid system mice.

Authors:  Alexandre P A Theocharides; Anthony Rongvaux; Kristin Fritsch; Richard A Flavell; Markus G Manz
Journal:  Haematologica       Date:  2016-01       Impact factor: 9.941

Review 4.  The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis.

Authors:  Erik R Nelson; Suzanne E Wardell; Donald P McDonnell
Journal:  Bone       Date:  2012-11-17       Impact factor: 4.398

5.  27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells.

Authors:  X Fu; J G Menke; Y Chen; G Zhou; K L MacNaul; S D Wright; C P Sparrow; E G Lund
Journal:  J Biol Chem       Date:  2001-08-14       Impact factor: 5.157

6.  From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs).

Authors:  Suzanne E Wardell; Erik R Nelson; Donald P McDonnell
Journal:  Steroids       Date:  2014-07-30       Impact factor: 2.668

7.  The oxysterol receptor LXR inhibits proliferation of human breast cancer cells.

Authors:  Lise-Lotte Vedin; Sebastian A Lewandowski; Paolo Parini; Jan-Ake Gustafsson; Knut R Steffensen
Journal:  Carcinogenesis       Date:  2009-01-23       Impact factor: 4.944

8.  Pharmacologic Activation of LXR Alters the Expression Profile of Tumor-Associated Macrophages and the Abundance of Regulatory T Cells in the Tumor Microenvironment.

Authors:  José M Carbó; Theresa E León; Joan Font-Díaz; Juan Vladimir De la Rosa; Antonio Castrillo; Felix R Picard; Daniel Staudenraus; Magdalena Huber; Lídia Cedó; Joan Carles Escolà-Gil; Lucía Campos; Latifa Bakiri; Erwin F Wagner; Carme Caelles; Thomas Stratmann; Jo A Van Ginderachter; Annabel F Valledor
Journal:  Cancer Res       Date:  2020-12-23       Impact factor: 12.701

Review 9.  Selective estrogen receptor modulators: tissue specificity and clinical utility.

Authors:  Stephen Martinkovich; Darshan Shah; Sonia Lobo Planey; John A Arnott
Journal:  Clin Interv Aging       Date:  2014-08-28       Impact factor: 4.458

10.  LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer.

Authors:  Katherine J Carpenter; Aurore-Cecile Valfort; Nick Steinauer; Arindam Chatterjee; Suomia Abuirqeba; Shabnam Majidi; Monideepa Sengupta; Richard J Di Paolo; Laurie P Shornick; Jinsong Zhang; Colin A Flaveny
Journal:  Sci Rep       Date:  2019-12-20       Impact factor: 4.379

View more
  1 in total

1.  ZMYND8 is a master regulator of 27-hydroxycholesterol that promotes tumorigenicity of breast cancer stem cells.

Authors:  Maowu Luo; Lei Bao; Yan Chen; Yuanyuan Xue; Yong Wang; Bo Zhang; Chenliang Wang; Chase D Corley; Jeffrey G McDonald; Ashwani Kumar; Chao Xing; Yisheng Fang; Erik R Nelson; Jennifer E Wang; Yingfei Wang; Weibo Luo
Journal:  Sci Adv       Date:  2022-07-15       Impact factor: 14.957

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.